OnCo
ideasIdea

Dose chemotherapy by muscle mass, not body surface area

Chemotherapy doses are calculated from height and weight, a formula from the 1950s. Doses based on actual muscle mass may cause fewer severe side-effects.

Body surface area poorly predicts clearance for most cytotoxics, and low lean body mass is associated with markedly higher rates of severe toxicity at standard doses, notably with fluoropyrimidines and taxanes. Lean mass is now measurable automatically from routine imaging, making an alternative dosing metric practical for the first time.

Hypothesis
Lean-mass-based dosing reduces grade 3 or higher toxicity by a third compared with body surface area dosing, without reducing dose intensity delivered per unit of lean tissue or compromising efficacy.
Rationale
Drug clearance tracks metabolically active tissue rather than total body size, which explains why sarcopenic patients are effectively overdosed. Pharmacogenomic dose adjustment for DPYD has already established that toxicity-driven dose individualisation is acceptable to clinicians and regulators.
What would test it
A randomised trial in one regimen with a high toxicity rate, comparing lean-mass dosing with standard dosing; primary endpoint severe toxicity, with pharmacokinetic sampling to confirm the mechanism.
Maturity
speculative
Who has to act
clinic
Cost to try
Medium ($1M to $50M)
Years to first evidence
5
Bottlenecks it attacks

Connected

12top

Pages like this

not linked directly; found by shared links